Browsing Tag
SanBio Co. Ltd.
1 post
Hopstem’s off-the-shelf neural cell therapy now targets three major brain injury markets
Two FDA clearances expand Hopstem’s hNPC01 into a three-indication neural cell platform spanning stroke and traumatic brain injury.